Doxorubicin ITC complaint
Executive Summary
Erbamont withdraws motion for a temporary exclusion order against Bristol-Myers and Cetus, filed with the company's complaint to the International Trade Commission in May. On Nov. 6, an administrative law judge will hear arguments for a permanent exclusion order against the importation of doxorubicin into the U.S. Bristol and Cetus began selling doxorubicin products in the U.S. in May upon the expiration of Erbamont's product patent for doxorubicin (Adriamycin). The complaint alleges that the two companies infringe Erbamont's process patent, which expires in 1991.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.